Abbott Laboratories Stock Falls 3% Following Narrowed Outlook

• Citigroup maintains a "Buy" rating for Abbott Laboratories (NYSE: ABT), with a current stock price of $124.17, indicating investor optimism.
• Abbott's diverse portfolio, healthy cash flow, and promising new product pipeline contribute to its positive outlook and growth potential.
• The company's stock has shown volatility but overall positive movement, with a trading volume of 10.76 million shares on the NYSE, reflecting active investor interest.

Abbott Laboratories (NYSE: ABT) is a global healthcare company known for its diverse portfolio, including medical devices, diagnostics, nutrition, and branded generic pharmaceuticals. The company competes with other healthcare giants like Johnson & Johnson and Medtronic. On July 18, 2025, Citigroup maintained its "Buy" rating for Abbott Labs, with the stock trading at around $124.50. The action associated with this rating is "hold," as highlighted by StreetInsider.

Abbott's strong buy recommendation for the second quarter of 2025 is supported by several factors. The company's robust management and diverse portfolio play a significant role in its positive outlook. Abbott's healthy cash flow and strategic capital return further enhance investor confidence. The promising pipeline of new products also contributes to the company's growth potential.

The current stock price of ABT is $124.17, showing an increase of approximately 3.04% or $3.66. This reflects investor optimism and confidence in the company's future prospects. Today, the stock has traded between a low of $122.27 and a high of $125.63, indicating some volatility but overall positive movement.

Over the past year, ABT has experienced a high of $141.23 and a low of $99.71. This range demonstrates the stock's potential for growth and the challenges it has faced. Despite these fluctuations, Abbott's market capitalization remains strong at approximately $216.04 billion, showcasing its stability and market presence.

The trading volume for ABT on the NYSE is 10.76 million shares, indicating active investor interest. This level of trading activity suggests that investors are closely monitoring Abbott's performance and are optimistic about its future. The combination of a strong buy recommendation, robust management, and a promising pipeline makes Abbott Laboratories an attractive investment opportunity.

Abbott Laboratories (NYSE:ABT) is a global healthcare company with a diverse portfolio that includes Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company has a strong presence in the healthcare sector, which has contributed to a positive sentiment among analysts. Over the past year, the consensus price target for Abbott has increased from $126.59 to $147, indicating growing optimism about its stock performance.

The company's advancements in medical devices and diagnostics, especially during the COVID-19 pandemic, have played a significant role in shaping analysts' positive outlook. Abbott's efforts in developing rapid diagnostic tests and other healthcare solutions have been well-received, further boosting confidence in its ability to innovate and perform well in the industry. This optimism is reflected in the steady consensus price target of $147 over the past month.

As Abbott prepares to announce its second-quarter earnings on July 17, 2025, analysts and investors are eagerly awaiting insights into the company's financial performance and future outlook. Analyst Marie Thibault from BTIG has set a price target of $130 for Abbott, suggesting a positive outlook for the company's stock performance. The upcoming earnings release is expected to provide valuable information on Abbott's growth prospects.

Abbott's FreeStyle Libre continuous glucose monitors (CGMs) and its Established Pharmaceuticals Division (EPD) business are driving positive momentum for the company. Key collaborations have expanded Abbott's global presence, making its CGMs more accessible to new patients. This expansion is expected to result in a compound annual growth rate (CAGR) of 15% in FreeStyle Libre sales by 2028, further supporting the positive sentiment among analysts.

Abbott's financial health is highlighted by its excellent balance sheet and a remarkable track record of over 50 consecutive years of dividend increases. This makes it an attractive long-term investment for income investors. The company's acquisition of rights to four more biosimilar products and a double-digit CAGR in target biosimilar emerging markets suggest that the EPD business could stimulate earnings per share (EPS) growth beyond its Medical Devices segment. Analyst Marie Thibault's price target of $130 reflects confidence in Abbott's growth prospects.

Abbott Laboratories (NYSE:ABT) delivered better-than-expected first-quarter earnings and held firm on its full-year guidance, even as parts of its business felt the impact of a challenging macro environment.

The company reported adjusted earnings of $1.09 per share for the quarter, surpassing analyst expectations of $1.07 and improving from $0.98 a year earlier. Total revenue rose 4% year-over-year to $10.36 billion, just shy of the $10.4 billion forecast.

One of the quarter’s key growth drivers was Abbott’s diabetes care segment, which saw a 16% surge in revenue to $1.83 billion, fueled by continued demand for its FreeStyle Libre glucose monitoring system. That strength helped push total medical device sales to $4.9 billion.

However, softness in the diagnostics division weighed on results, with revenue from that unit falling 7.2% to $2.05 billion—below analysts’ estimates of $2.19 billion.

Despite mixed segment performance, Abbott reiterated its full-year 2025 guidance. The company still expects organic sales growth between 7.5% and 8.5%, and adjusted EPS in the range of $5.05 to $5.25. For the current quarter, adjusted earnings are projected between $1.23 and $1.27 per share.

Abbott Laboratories (NYSE:ABT) delivered better-than-expected first-quarter earnings and held firm on its full-year guidance, even as parts of its business felt the impact of a challenging macro environment.

The company reported adjusted earnings of $1.09 per share for the quarter, surpassing analyst expectations of $1.07 and improving from $0.98 a year earlier. Total revenue rose 4% year-over-year to $10.36 billion, just shy of the $10.4 billion forecast.

One of the quarter’s key growth drivers was Abbott’s diabetes care segment, which saw a 16% surge in revenue to $1.83 billion, fueled by continued demand for its FreeStyle Libre glucose monitoring system. That strength helped push total medical device sales to $4.9 billion.

However, softness in the diagnostics division weighed on results, with revenue from that unit falling 7.2% to $2.05 billion—below analysts’ estimates of $2.19 billion.

Despite mixed segment performance, Abbott reiterated its full-year 2025 guidance. The company still expects organic sales growth between 7.5% and 8.5%, and adjusted EPS in the range of $5.05 to $5.25. For the current quarter, adjusted earnings are projected between $1.23 and $1.27 per share.

• Abbott Laboratories (NYSE:ABT) reported an EPS of $1.09, surpassing estimates and showing improvement from the previous year.
• The company's revenue of $10.36 billion fell slightly short of estimates, but it reaffirmed its annual guidance with robust growth projections.
• Abbott's financial health is solid, with a P/E ratio of approximately 17.08 and a debt-to-equity ratio of approximately 0.32, indicating moderate debt levels and strong market valuation.

Abbott Laboratories, listed as NYSE:ABT, is a global healthcare company known for its diverse range of products, including medical devices, diagnostics, and nutritional products. The company competes with other major healthcare firms like Johnson & Johnson and Medtronic. Abbott's focus on innovation and quality has helped it maintain a strong position in the healthcare industry.

On April 16, 2025, Abbott reported earnings per share (EPS) of $1.09, surpassing the estimated $1.07. This performance marks an improvement from the previous year's EPS of $0.98, as highlighted by Zacks. Despite this earnings beat, the company's revenue of $10.36 billion fell slightly short of the estimated $10.41 billion.

Abbott's stock experienced a slight decline following the release of its first-quarter results, with a premarket trading price of $125.77. Despite the sales miss, the company reaffirmed its annual guidance, projecting adjusted earnings between $5.05 and $5.25 per share and organic sales growth of 7.5% to 8.5%. Analysts had forecasted earnings of $5.15 per share and total sales of $44.41 billion for the year.

The company's strong performance in the first quarter was driven by robust demand for its diabetes care products and other medical devices. This focus on the medical device segment has been a key growth area for Abbott. The company's price-to-earnings (P/E) ratio of approximately 17.08 indicates the market's valuation of its earnings, while its price-to-sales ratio of about 5.46 reflects the market's valuation of its revenue.

Abbott's financial health is further supported by its debt-to-equity ratio of approximately 0.32, suggesting a moderate level of debt relative to equity. The company's current ratio of about 1.67 indicates its ability to cover short-term liabilities with short-term assets. Additionally, Abbott's enterprise value to sales ratio is around 5.64, and its enterprise value to operating cash flow ratio is approximately 27.65, providing insights into its valuation relative to sales and cash flow.

• Abbott Laboratories (NYSE:ABT) reported an EPS of $1.09, surpassing estimates and showing improvement from the previous year.
• The company's revenue of $10.36 billion fell slightly short of estimates, but it reaffirmed its annual guidance with robust growth projections.
• Abbott's financial health is solid, with a P/E ratio of approximately 17.08 and a debt-to-equity ratio of approximately 0.32, indicating moderate debt levels and strong market valuation.

Abbott Laboratories, listed as NYSE:ABT, is a global healthcare company known for its diverse range of products, including medical devices, diagnostics, and nutritional products. The company competes with other major healthcare firms like Johnson & Johnson and Medtronic. Abbott's focus on innovation and quality has helped it maintain a strong position in the healthcare industry.

On April 16, 2025, Abbott reported earnings per share (EPS) of $1.09, surpassing the estimated $1.07. This performance marks an improvement from the previous year's EPS of $0.98, as highlighted by Zacks. Despite this earnings beat, the company's revenue of $10.36 billion fell slightly short of the estimated $10.41 billion.

Abbott's stock experienced a slight decline following the release of its first-quarter results, with a premarket trading price of $125.77. Despite the sales miss, the company reaffirmed its annual guidance, projecting adjusted earnings between $5.05 and $5.25 per share and organic sales growth of 7.5% to 8.5%. Analysts had forecasted earnings of $5.15 per share and total sales of $44.41 billion for the year.

The company's strong performance in the first quarter was driven by robust demand for its diabetes care products and other medical devices. This focus on the medical device segment has been a key growth area for Abbott. The company's price-to-earnings (P/E) ratio of approximately 17.08 indicates the market's valuation of its earnings, while its price-to-sales ratio of about 5.46 reflects the market's valuation of its revenue.

Abbott's financial health is further supported by its debt-to-equity ratio of approximately 0.32, suggesting a moderate level of debt relative to equity. The company's current ratio of about 1.67 indicates its ability to cover short-term liabilities with short-term assets. Additionally, Abbott's enterprise value to sales ratio is around 5.64, and its enterprise value to operating cash flow ratio is approximately 27.65, providing insights into its valuation relative to sales and cash flow.

Abbott Laboratories, listed as NYSE:ABT, is a global healthcare company known for its diverse range of products, including medical devices, diagnostics, and nutritional products. The company is a key player in the healthcare sector, competing with other giants like Johnson & Johnson and Medtronic. Abbott's upcoming earnings release on April 16, 2025, is highly anticipated by investors and analysts alike.

For the quarter ending March 2025, analysts expect Abbott to report earnings per share (EPS) of $1.07, reflecting a 9.2% increase from the previous year. This growth is supported by projected revenues of $10.42 billion, a 4.5% rise year-over-year. The slight upward revision of the EPS estimate by 0.1% over the past 30 days suggests a positive outlook from analysts, as highlighted by Zacks Investment Research.

Abbott's Medical Devices segment, particularly its Structural Heart, Rhythm Management, and Neuromodulation businesses, is expected to have played a significant role in the company's performance this quarter. The focus on these areas indicates a strategic emphasis on high-growth sectors within the healthcare industry, which could drive future revenue and earnings growth.

The company's financial metrics provide further insights into its valuation. Abbott's price-to-earnings (P/E) ratio of 16.53 suggests a moderate market valuation of its earnings, while its price-to-sales ratio of 5.29 reflects the market's valuation of its revenue. Additionally, the enterprise value to sales ratio of 5.47 and enterprise value to operating cash flow ratio of 26.80 offer perspectives on its valuation relative to sales and cash flow.

Abbott's financial health is underscored by its debt-to-equity ratio of 0.32, indicating a moderate level of debt compared to equity. The current ratio of 1.67 suggests that the company is well-positioned to cover its short-term liabilities with its short-term assets. These metrics, combined with an earnings yield of 6.05%, provide a comprehensive view of Abbott's financial standing as it approaches its earnings release.